Kevin Kunzmann

The Icahn investigator reviews new data suggesting ethnicity-based differences in molecular phenotype of atopic dermatitis, which may better inform treatment strategies for different populations.

New phase 3 DELTA 1 trial data show the topical pan-JAK inhibitor doubled the rate of treatment success versus vehicle cream.

New long-term extension data from the pivotal TRuE-V program show treatment continuation, as well as post-relapse re-initiation, is efficacious and safe in patients.

After last year's historic approval, investigators want to learn more about their available drug regimens, as well as pediatric eligibility.

Three years into the pandemic, dermatologists have become more confident in discussing vaccine issues with their patients, including the misunderstood risk of disease flare-up associated with boosters.

The University of Toronto expert discusses therapy switching, JAK inhibitor initiation, comorbidity cross-benefit, and more at AAD 2023.

Amid the introduction of immunosuppressant therapies and the ongoing pandemic, dermatologists find themselves guiding new decisions for patient treatment around vaccinations.

Little head-to-head data exists between JAK inhibitors and biologics, but common metrics of treatment success can help physicians navigate newer agents.

The UMass Chan chair of dermatology recaps a historic year of development for the chronic disease, including the progression of even newer treatment options.

The Mount Sinai Dermatology chair reviews headlines from the 2022 meeting before sharing perspective on developing drugs and topics.

Beyond the obvious benefits, the practice of remote and in-clinic photography is altering treatment capabilities.

The St. Jude oncologist discusses the 30-year development of pediatric melanoma interpretation.

In addition to sharing how a novel machine learning method may one day soon predict lung disease susceptibility, Kalhan describes the science behind the ALA Lung Health Cohort Research Study.

A new review considered the progression of 4 treatment options being researched and developed for the treatment of the progressive form of vision loss.

A new survey analysis delves into Americans' perspective on the CDC, and local and state health departments, and their handling of the pandemic.

A new study from China shows predictive value of baseline PCV presence and PED characteristics among patients with nAMD receiving conbercept.

A one-of-its-kind assessment of 8 decades' worth of UK data show a lower respiratory tract infection by age 2 increases risk of premature adult death by 93%.

A new study supports an individualized treatment plan for aflibercept, showing its improved efficacy with fewer injections over 2 years.

The approval for omaveloxolone was supported by open-label data showing benefit of care for up to 3 years.

Cytokinetics announced the CRL on Tuesday, as well as their intentions to forego any future clinical trials for the agent while focusing on the development of aficamten.

Verrica Pharmaceutical's drug-device combination will be decided upon as potentially the first molluscum drug in July.

The company announced more feedback from the FDA after receiving a Complete Response Letter last March.

The US disproportionately arrests individuals with mental illness, and relies on police officers to respond to health crises. Practical, preventive clinical measures need to help stop the cycle.

New data show the FDA's rationale for approving drugs with unmet efficacy end points in pivotal trials has been inconsistent since at least 2018.

David Tom Cooke, MD, reviewed the importance of shared decision making as it relates to risk and benefit of cancer screening, as well as in more refined invasive care options.

Cooke joins the first episode of 2023 to discuss his colleague’s specific role in lung cancer screening and intervention and advances to minimally invasive, robotic and bronchoscopic techniques.

Amid a blood shortage and continued stigmatization of HIV risk, it's hard to feel good about the FDA's delayed decision—though good may still come of it.

An FDA panel voted unanimously this week to support harmonizing an annual primary and booster dose, moving public health strategies to reflect the endemic course of COVID-19.

A new review shows a majority of COVID-19 randomized, controlled trial preprints have been published with changes to the components of the original findings.

After addressing a 2021 CRL, Verrica Pharmaceuticals vies for the agent to become the first drug approved to treat the common skin infection.